Your browser doesn't support javascript.
loading
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Jardine, Meg; Zhou, Zien; Lambers Heerspink, Hiddo J; Hockham, Carinna; Li, Qiang; Agarwal, Rajiv; Bakris, George L; Cannon, Christopher P; Charytan, David M; Greene, Tom; Levin, Adeera; Li, Jing-Wei; Neuen, Brendon L; Neal, Bruce; Oh, Richard; Oshima, Megumi; Pollock, Carol; Wheeler, David C; de Zeeuw, Dick; Zhang, Hong; Zinman, Bernard; Mahaffey, Kenneth W; Perkovic, Vlado.
Afiliação
  • Jardine M; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • Zhou Z; Renal Department, Concord Repatriation General Hospital, Sydney, Australia.
  • Lambers Heerspink HJ; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • Hockham C; Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Li Q; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • Agarwal R; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Bakris GL; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • Cannon CP; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • Charytan DM; Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana.
  • Greene T; Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana.
  • Levin A; Department of Medicine, University of Chicago Medicine, Chicago, Illinois.
  • Li JW; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
  • Neuen BL; Nephrology Division, New York University School of Medicine and New York University Langone Medical Center, New York, New York.
  • Neal B; Baim Institute for Clinical Research, Boston, Massachusetts.
  • Oh R; Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.
  • Oshima M; Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Pollock C; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • Wheeler DC; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • de Zeeuw D; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • Zhang H; Charles Perkins Centre, University of Sydney, Sydney, Australia.
  • Zinman B; School of Public Health, Imperial College London, London, United Kingdom.
  • Mahaffey KW; Metabolism, Janssen Research and Development, LLC, Raritan, New Jersey.
  • Perkovic V; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
Clin J Am Soc Nephrol ; 16(3): 384-395, 2021 03 08.
Article em En | MEDLINE | ID: mdl-33619120
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Albuminúria / Canagliflozina / Inibidores do Transportador 2 de Sódio-Glicose / Nefropatias Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Albuminúria / Canagliflozina / Inibidores do Transportador 2 de Sódio-Glicose / Nefropatias Idioma: En Ano de publicação: 2021 Tipo de documento: Article